Longevity / NAD+ Precursors Compared: NMN, NR, Niacin, and NAM

NAD+ Precursors Compared: NMN, NR, Niacin, and NAM

Written by

Sophie Chabloz

Most articles about NAD+ supplements stop at NMN versus NR. The full precursor landscape is broader than that. Niacin and nicotinamide (NAM) have been used as B-vitamin supplements for decades. Each of the four major precursors enters the salvage pathway at a different point and carries a different evidence profile. This piece compares them, names the trade-offs, and points to which one fits which situation.

In this article:

The salvage pathway and where each precursor enters
Niacin (nicotinic acid): the original NAD+ booster
Nicotinamide (NAM): the B3 form most commonly added to food
NR (nicotinamide riboside): the licensed precursor
NMN (nicotinamide mononucleotide): the closest to NAD+
Side-by-side comparison
Where to go next

The salvage pathway and where each precursor enters

Your cells make NAD+ from raw material via the salvage pathway. Different precursors feed in at different points. The closer a precursor sits to NAD+ itself, the fewer enzymatic steps are required for conversion. Bogan and Brenner’s 2008 review remains the foundational map of these pathways.

Niacin enters earliest. Through the Preiss-Handler pathway, it’s converted via NAPRT to nicotinic acid mononucleotide, then to NAAD, then to NAD+. Three enzymatic steps.

Nicotinamide (NAM) enters via NAMPT, the rate-limiting enzyme that becomes less efficient with age. NAMPT converts NAM into NMN, then NMNAT converts NMN to NAD+. Two steps, but one is bottlenecked.

NR enters via the nucleoside transporters and is phosphorylated by NRK to NMN, then converted by NMNAT to NAD+. Two steps, neither bottlenecked by age.

NMN enters via Slc12a8 and other transporters and is converted directly by NMNAT to NAD+. One step.

These differences matter at the cellular level but matter less than people assume at the whole-body level. All four precursors raise blood NAD+ at adequate doses. The differences are in the rate of conversion, the regulatory context, and the dose required.

Niacin (nicotinic acid): the original NAD+ booster

Niacin has been used in supplements and prescription medicine for decades. It’s the form of vitamin B3 most often used in cholesterol management, and at higher doses it raises NAD+ measurably.

The case for niacin: cheap, well-studied, GRAS for decades, effective at raising NAD+. The case against: at the doses needed for a meaningful NAD+ effect (typically 500-1000 mg per day or higher), niacin causes a flushing reaction in most people. The flush is a prostaglandin-mediated vasodilation, driven mainly by prostaglandin D2 – harmless but uncomfortable, with skin reddening, warmth, and sometimes itching for 30 to 60 minutes after a dose. (It’s why taking aspirin beforehand, which blocks prostaglandin production, blunts the flush.)

The receptor behind that reaction is HCA2 (also called GPR109A), which niacin activates and NMN and NR don’t. It produces some of niacin’s distinctive effects on lipid metabolism, but it also limits niacin’s usefulness as a clean NAD+-raising tool.

In practice, niacin is rarely used in modern longevity protocols specifically for NAD+ purposes. It’s a useful B-vitamin and a legitimate cholesterol intervention, but as a precursor, the side effect profile pushes most users toward NMN, NR, or NAM.

Nicotinamide (NAM): the B3 form most commonly added to food

NAM is the B3 form added to fortified breads, cereals, and most multivitamin formulas. It enters NAD+ biosynthesis through NAMPT, the same bottlenecked enzyme that limits the salvage pathway.

The case for NAM: extremely well-tolerated, no flushing, inexpensive, used safely for decades. Useful as a general B3 source. The case against: because NAM enters at the NAMPT bottleneck, it’s the least efficient precursor for raising NAD+ in older adults whose NAMPT activity is already reduced. You’re feeding the system at exactly the point where it can’t process more.

NAM also has a separate biological activity: it’s a sirtuin inhibitor at high concentrations. The very enzymes you’re trying to support with elevated NAD+ become less active in the presence of high NAM. This is one reason high-dose NAM hasn’t gained traction as a longevity strategy despite being cheaper than NMN.

The AVEA Booster contains 16 mg of nicotinamide alongside other longevity-relevant compounds. At that dose, it serves as B3 nutrition rather than NAD+-raising therapy. We cover niacinamide as a B3 source in more detail at https://insights.avea-life.com/longevity/niacinamide-supplement/.

NR (nicotinamide riboside): the licensed precursor

NR is the most regulatorily settled precursor in this list. It has GRAS status in the US and has been authorised as a novel food in the EU. Several large brands sell NR-based products with full regulatory clarity.

The case for NR: strong safety record across multi-year trials, broad availability, regulatory clarity, no flushing. Effective at raising blood NAD+ at 250-1000 mg per day. The case against: human functional-outcome data has been more mixed than NMN’s. Some trials show clear benefit, others show NAD+ rising without clear functional change. Cost has historically been higher than NMN due to patent-protected supply.

NR’s mechanism is simple: it enters cells through nucleoside transporters and gets phosphorylated to NMN inside, then converted to NAD+. The conversion is straightforward but adds one enzymatic step compared with NMN.

Practically, NR is the right choice when regulatory clarity matters, or when you’ve tried NMN without success and want to see whether a slightly different molecule produces a different individual response.

NMN (nicotinamide mononucleotide): the closest to NAD+

NMN is one biochemical step from NAD+. The NMNAT enzymes convert it directly. Across human trials it has the strongest functional-outcomes record among the four precursors, with improvements reported in blood NAD+, walking distance, physical performance, and insulin sensitivity (Yoshino et al., 2021; Pencina et al., 2023; Igarashi et al., 2022), building on the animal work that first demonstrated the effect (Mills et al., 2016).

The case for NMN: closest to NAD+, strongest recent human trial data, no flushing. The case against: its regulatory status varies by market and is still settling; manufacturing quality has historically been more variable; and cost is generally higher than NAM or niacin.

For most adults pursuing an evidence-based approach to NAD+ restoration, NMN at 250-500 mg per day is the precursor with the most defensible current data. AVEA NMN uses Longevir, the only NMN currently manufactured in Europe at this scale and quality, with batch-level Swiss lab verification.

Side-by-side comparison

A summary that may help when deciding.

Steps to NAD+: niacin three, NAM two (with a bottleneck), NR two, NMN one.

Cost per effective dose: niacin lowest, NAM very low, NR moderate-to-high, NMN moderate-to-high.

Side effects: niacin causes flushing at NAD+-relevant doses; the others are generally well-tolerated.

Regulatory clarity: NAM and niacin fully clear in all major markets; NR fully clear in the US and EU; NMN clearer than it was (lawful in the US as of 2025, EU authorisation pending) but still varying by market.

Strength of human functional evidence: NMN strongest in recent trials; NR second; NAM and niacin minimal at NAD+-relevant doses.

Practical recommendation for most adults seeking NAD+ restoration: NMN at 250-500 mg per day from a verified-quality manufacturer. NR if regulatory comfort or an established track record matters more than the latest functional-outcomes data. NAM and niacin as supportive B3 nutrition rather than primary NAD+ strategies.

Where to go next

If you want a closer head-to-head on the two precursors most people choose between, NMN vs NR (nicotinamide riboside): the complete comparison goes deeper. If dose is the next question, NMN dosage: 250 mg vs 500 mg vs higher amounts covers the dose-response evidence. And “NAD+ Decline and How to Restore It” brings everything into one frame.